On Wednesday, Shares of Pandora Media Inc (NYSE:P), subtract -2.31% and closed at $13.33 in the last trading session. The last trading range of the stock ranges between $13.28 and $13.62. The company’s Market capitalization is $2.97 Billion with the total Outstanding Shares of 224.97 million. During the 52-week trading session the minimum price at which share price traded, registered at $7.10 and reached to max level of $20.64. Pandora (NYSE:P), the go-to music source for fans and artists, recently declared that its third quarter 2016 financial results will be released on Tuesday, October 25, 2016, after the close of the market. The company will also host an “in-person” event and webcast at 1:30 PM (PT) / 4:30 PM (ET) designed to provide financial analysts an opportunity to hear from members of the Pandora leadership team and discuss Pandora’s planned vision in light of the recently declared product transformation and landmark label deals. Presentations will highlight new product features, operating model developments, and key operating and financial metrics in the context of existing 2020 targets for ad-supported, subscription, and live events businesses.
Galena Biopharma Inc (NASDAQ:GALE), dropped -3.82% and closed at $0.277 in the last trading session. The last trading range of the stock ranges between $0.26 and $0.29. The company’s Market capitalization is $56.46 Billion with the total Outstanding Shares of 214.48 million. During the 52-week trading session the minimum price at which share price traded, registered at $0.26 and reached to max level of $2.49. Galena Biopharma, Inc. (GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs, presented interim safety data from the Company’s NeuVax™ (nelipepimut-S) Phase 2b combination study with trastuzumab at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark. The clinical trial is a randomized, multicenter, investigator-sponsored, 300 patient Phase 2b study. It is presently enrolling HER2 1+ and 2+ node positive, and high-risk node negative patients to study NeuVax in combination with trastuzumab to prevent breast cancer recurrence
Poster #1069P, entitled “Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression,” demonstrated that this novel combination of trastuzumab and NeuVax in HER2 low-expressing (LE) patients is well-tolerated and the cardiac effects of trastuzumab are not influenced by the addition of NeuVax.
Eli Lilly and Co (NYSE:LLY), lost 1.59% and closed at $80.51 in the last trading session. The last trading range of the stock ranges between $80.46 and $82.22. During the 52-week trading session the minimum price at which share price traded, registered at $67.88 and reached to max level of $88.16. HMS Holdings Corp. (HMSY) recently declared that Alex Michael Azar II has been designated to the HMS Board of Directors, effective October 11, 2016. Mr. Azar is President, Lilly USA, LLC, the leading associate of Eli Lilly & Company (LLY). Before joining Lilly, Mr. Azar was the Deputy Secretary (2005-2007) and General Counsel (2001-2005) at the U.S. Department of Health & Human Services.
“Alex Azar brings an important blend of government and industry experience to our Board,” said Bill Lucia, Chairman and CEO. “He has an informed perspective on healthcare policy which will enrich our Board dialogue. In addition, Alex has extensive experience with big data in his current role at Lilly which is particularly relevant as we expand into the care administration and data analytics field with our recent acquisition of Essette.”
Before his service at HHS, Mr. Azar was in private legal practice. He is a graduate of Dartmouth College and the Yale Law School, and was a Law Clerk to U.S. Supreme Court Justice Antonin Scalia.